Memantine offers new possibilities for the treatment of VaD.
Winblad
Bengt
B
Karolinska Institutet, NEUROTEC, Division of Geriatric Medicine and Geriatric Epidemiology, Huddinge University Hospital, 141 86 Stockholm, Sweden. Bengt.Winblad@neurotec.ki.se
Kivipelto
Miia
M
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects; D015140:Dementia, Vascular / Q000188:drug therapy*; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D008559:Memantine / Q000627:therapeutic use*; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use
D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents; D008559:Memantine